Since 1995, Halford had been conducting and publishing research
on the herpes simplex virus, for which he had received small grants from the National Institutes of Health. But the biology professor at Southern Illinois University had run out of time. Diagnosed in 2011 with sinonasal undifferentiated carcinoma, a rare form of cancer,
Halford knew that he might not be able to complete development of his vaccine and gain approval from the US Food and Drug Administration before his life ended. In fact, when Halford died of cancer in June at the age of 48, his vaccine had not cleared all the regulatory hurdles necessary for a medical product to be approved for use in the US. Now, the FDA has launched a criminal investigation into Halford’s research practices, according to a report by Kaiser Health News.